Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS By Investing.com
© Reuters. After-Hours Stock Movers: Spectrum Pharmaceuticals (NASDAQ:) 28% LOWER; The FDA’s Oncologic Drugs Advisory Committee (ODAC) met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. The committee voted 9-4 that the current benefits of poziotinib did …
Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS By Investing.com Read More »